H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO)

October 16, 2026 8:08 AM

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $50.00 price target on Sutro Biopharma (NASDAQ: STRO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found